Literature DB >> 21740095

Quality of life appears similar between survivors of indolent and aggressive non-Hodgkin lymphoma.

Anne H Blaes1, Linan Ma, Yan Zhang, Bruce A Peterson.   

Abstract

Few studies have examined the quality of life (QOL) in survivors of non-Hodgkin lymphoma (NHL). A total of 109 patients with NHL (58 aggressive [AGG], 51 indolent [IND]) completed two health-related QOL assessments using the Medical Outcomes Study 36-Item Short-Form Healthy Survey (MOS SF-36) and the Functional Assessment in Cancer Therapy - Fatigue (FACT-F). Scores between IND and AGG were compared using a two-sample t-test. Multiple linear regression was performed to account for any potentially explanatory variables. Overall, 70.6% had received chemotherapy and 55% had received immunotherapy. Some 17.6% of the IND group had received no therapy. The overall physical and mental component QOL scores of the SF-36 did not differ between survivors. Physical function in survivors of IND was significantly better when compared with that of AGG NHL. Our study reports a similar overall QOL between survivors of IND and AGG NHL. Physical function, however, may be more impaired in survivors of AGG NHL.

Entities:  

Mesh:

Year:  2011        PMID: 21740095      PMCID: PMC4499509          DOI: 10.3109/10428194.2011.593270

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  20 in total

1.  Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy.

Authors:  Jeanette Doorduijn; Ivonne Buijt; Bronno Holt; Monique Steijaert; Carin Uyl-de Groot; Pieter Sonneveld
Journal:  Eur J Haematol       Date:  2005-08       Impact factor: 2.997

2.  Epidemiology of non-Hodgkin lymphoma in Connecticut. 1935-1988.

Authors:  T Zheng; S T Mayne; P Boyle; T R Holford; W L Liu; J Flannery
Journal:  Cancer       Date:  1992-08-15       Impact factor: 6.860

3.  A validation study of the Dutch version of the Quality of Life-Cancer Survivor (QOL-CS) questionnaire in a group of prostate cancer survivors.

Authors:  Femke W van Dis; Floortje Mols; Ad J J M Vingerhoets; Betty Ferrell; Lonneke V van de Poll-Franse
Journal:  Qual Life Res       Date:  2006-07-07       Impact factor: 4.147

4.  Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study.

Authors:  Patricia A Ganz; Katherine A Desmond; Beth Leedham; Julia H Rowland; Beth E Meyerowitz; Thomas R Belin
Journal:  J Natl Cancer Inst       Date:  2002-01-02       Impact factor: 13.506

5.  Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors.

Authors:  Sophia K Smith; Sheryl Zimmerman; Christianna S Williams; John S Preisser; Elizabeth C Clipp
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

Review 6.  Lymphoma in older patients.

Authors:  Catherine Thieblemont; Bertrand Coiffier
Journal:  J Clin Oncol       Date:  2007-05-10       Impact factor: 44.544

7.  Health status and quality of life among non-Hodgkin lymphoma survivors.

Authors:  Sophia K Smith; Sheryl Zimmerman; Christianna S Williams; Bradley J Zebrack
Journal:  Cancer       Date:  2009-07-15       Impact factor: 6.860

8.  Trends in cancer incidence and mortality.

Authors:  M P Coleman; J Estève; P Damiecki; A Arslan; H Renard
Journal:  IARC Sci Publ       Date:  1993

9.  Quality of life of long-term survivors of non-small-cell lung cancer.

Authors:  Linda Sarna; Geraldine Padilla; Carmack Holmes; Donald Tashkin; Mary Lynn Brecht; Lorraine Evangelista
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

10.  Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor Study.

Authors:  Brad J Zebrack; Lonnie K Zeltzer; John Whitton; Ann C Mertens; Lorrie Odom; Roger Berkow; Leslie L Robison
Journal:  Pediatrics       Date:  2002-07       Impact factor: 9.703

View more
  6 in total

1.  A high level of fatigue among long-term survivors of non-Hodgkin's lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands.

Authors:  Simone Oerlemans; Floortje Mols; Djamila E Issa; J H F M Pruijt; Wim G Peters; Marnix Lybeert; Wobbe Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

2.  Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma.

Authors:  Anne W Beaven; Greg Samsa; Sheryl Zimmerman; Sophia K Smith
Journal:  Cancer Invest       Date:  2016-07-05       Impact factor: 2.176

3.  The association of health behaviors with quality of life in lymphoma survivors.

Authors:  Priyanka A Pophali; Melissa C Larson; Allison C Rosenthal; Dennis Robinson; Thomas M Habermann; Gita Thanarajasingam; Timothy Call; Cristine Allmer; Umar Farooq; Matthew J Maurer; Kathleen J Yost; James R Cerhan; Carrie A Thompson
Journal:  Leuk Lymphoma       Date:  2020-10-13

Review 4.  Health-Related Quality of Life and Treatment of Older Adults with Acute Myeloid Leukemia: a Young International Society of Geriatric Oncology Review Paper.

Authors:  Kah Poh Loh; Maya Abdallah; Anita J Kumar; Nina R Neuendorff; Saurabh Dahiya; Heidi D Klepin
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 4.213

5.  Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study.

Authors:  Danbee Kang; Juhee Cho; Im Ryung Kim; Mi Kyung Kim; Won Seog Kim; Seok Jin Kim
Journal:  Cancer Res Treat       Date:  2017-11-09       Impact factor: 4.679

6.  Disability, psychological distress and quality of life in relation to cancer diagnosis and cancer type: population-based Australian study of 22,505 cancer survivors and 244,000 people without cancer.

Authors:  Grace Joshy; Joanne Thandrayen; Bogda Koczwara; Phyllis Butow; Rebekah Laidsaar-Powell; Nicole Rankin; Karen Canfell; John Stubbs; Paul Grogan; Louise Bailey; Amelia Yazidjoglou; Emily Banks
Journal:  BMC Med       Date:  2020-12-01       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.